A efetividade da imunoterapia em diferentes tipos de câncer: um estudo ciênciometrico
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Avaliar a efetividade da imunoterapia em uma ampla gama de neoplasias. Métodos: Estudo cienciométrico utilizando as bases de dados PubMed, Scientific Electronic Library Online (Scielo) e Science Direct. Seguiu critérios de inclusão que abrangem artigos publicados nacional e internacionalmente, sem restrição de período de publicação e em estudos clínicos e pesquisas de análise disponíveis gratuitamente. Para o tratamento dos dados foram empregados programas como VosViewer, Mendeley e Excel. Resultados: Foram incluídos 32 artigos. A publicação dos artigos varia de 1969 a 2024, oferecendo uma visão abrangente da evolução da pesquisa em imunoterapia ao longo de mais de meio século. Isso permite aos pesquisadores traçar o progresso e identificar áreas de crescimento e interesse contínuo. Observou-se um aumento notável na quantidade de pesquisas publicadas nos anos mais recentes, refletindo um interesse cada vez maior e um maior investimento na área de imunoterapia contra o câncer. Conclusão: Estudos sobre a temática está em uma trajetória promissora, com avanços significativos e um futuro repleto de potencial. A medicina de precisão, a tecnologia de ponta e a colaboração internacional estão impulsionando essa área, tornando-a uma parte essencial da oncologia moderna.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ASCIERTO PA, et al. Epithelioid cell-type melanoma as a prognostic factor of poor response to immunological treatment. Annals of Oncology, 2000; 1504.
3. BANDO H, et al. Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. Clinical Colorectal Cancer, 2022; 3–9.
4. BARBIERI C, et al. Effect of surgical treatment on the cellular immune response of gastric cancer patients. Brazilian Journal of Medical and Biological Research, 2003; 339–345.
5. BARROS L, et al. Immunological-based approaches for cancer therapy. Clinics, 2018; 429.
6. CHIRIVA-INTERNATI M. Immunological treatment of liver tumors. World Journal of Gastroenterology, 2005; 6571.
7. CHIRIVA-INTERNATI M, et al. Cancer immunotherapy: avoiding the road to perdition. Journal of Translational Medicine, 2004; 26.
8. GUO C, et al. Tumor immunological phenotype-derived gene classification predicts prognosis, treatment response, and drug candidates in ovarian cancer. Genes & Diseases, 2024; 101173.
9. HADILOO K, et al. The new era of immunological treatment, last updated and future consideration of CAR T cell-based drugs. Pharmacological Research, 2024; 107158.
10. HAWLEY JE, et al. Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer. Cancer Cell, 2023; 1972-19885.
11. HUNG SI, et al. Personalized neoantigen-based T cell therapy triggers cytotoxic lymphocytes expressing polyclonal TCR against metastatic ovarian cancer. Biomedicine & Pharmacotherapy, 2023; 115928.
12. JANICZEK M, et al. Immunotherapy as a Promising Treatment for Prostate Cancer: A Systematic Review. Journal of Immunology Research, 2017; 1–6.
13. KHAN JA e YAQIN S. Dendritic cell therapy with improved outcome in glioma multiforme—A case report. Journal of Zhejiang University SCIENCE B, 2006; 114–117.
14. KHAN JA e YAQIN S. Successful immunological treatment of gallbladder cancer in India—Case report. Journal of Zhejiang University SCIENCE B, 2006; 719–724.
15. LIN MH, et al. Immunological evaluation of a novel HLA-A2 restricted phosphopeptide of tumor associated Antigen, TRAP1, on cancer therapy. Vaccine: X, 2019; 100017.
16. LÓPEZ M, et al. Avances en inmunoterapia celular contra el melanoma maligno. Revista Médica de Chile, 2004.
17. MATHE G. Approaches to the immunological treatment of cancer in man. BMJ, 1969; 7–10.
18. MATHE G. Immunological treatment of leukaemias. BMJ, 1970; 487–488.
19. MOKKAPATI S, et al. Lentiviral interferon: A novel method for gene therapy in bladder cancer. Molecular Therapy - Oncolytics, 2022;141–157.
20. NAGORSEN D e THIEL E. HLA typing demands for peptide-based anti-cancer vaccine. Cancer Immunology, Immunotherapy, 2008; 1903–1910.
21. PORTER LH, et al. Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies. The Journal of Steroid Biochemistry and Molecular Biology, 2024; 106571.
22. QI L, et al. Twenty years of Gendicine® rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology. Genes & Diseases, 2024; 101155.
23. RANGEL-SOSA MM, et al. Imunoterapia e terapia genética como novos tratamentos para o câncer. Colombia Médica, 2017; 138–147.
24. SANDOVAL-VALENCIA RR. Cancer immunotherapy: Role of the immune system in malignant transformation. Revista Médica Del Hospital General de México, 2019.
25. SCHUTT C, et al. Immunological Treatment Options for Locoregionally Advanced Head and Neck Squamous Cell Carcinoma. International Reviews of Immunology, 2012; 22–42.
26. SONG J e WU L. Friend or Foe: Prognostic and Immunotherapy Roles of BTLA in Colorectal Cancer. Frontiers in Molecular Biosciences, 2020.
27. VAN GENUGTEN EAJ, et al. Imaging the Rewired Metabolism in Lung Cancer in Relation to Immune Therapy. Frontiers in Oncology, 2022.
28. WÜRFEL FM, et al. European Patent in Immunoncology: From Immunological Principles of Implantation to Cancer Treatment. International Journal of Molecular Sciences, 2019; 1830.
29. XIE W, et al. The Destruction Of Laser-Induced Phase-Transition Nanoparticles Triggered By Low-Intensity Ultrasound: An Innovative Modality To Enhance The Immunological Treatment Of Ovarian Cancer Cells. International Journal of Nanomedicine, 2019; 9377–9393.
30. YANG Y, et al. Identification and Validation of Efficacy of Immunological Therapy for Lung Cancer From Histopathological Images Based on Deep Learning. Frontiers in Genetics, 2021.
31. YOUNG MRI. Redirecting the focus of cancer immunotherapy to premalignant conditions. Cancer Letters, 2017; 83–88.
32. ZENG H, et al. Diagnostic, prognostic, and immunological roles of CDSN in ovarian cancer. Heliyon, 2024, 33357.